Drug Detail:Nuzyra (oral/injection) (Omadacycline (oral/injection) [ oh-ma-da-sye-kleen ])
Generic Name: omadacycline 100mg in 5mL
Dosage Form: injection, powder, lyophilized, for solution
Drug Class: Tetracyclines
Important Administration Instructions
Dosage in Adults with Community-Acquired Bacterial Pneumonia (CABP)
For treatment of adults with CABP the recommended dosage regimen (loading and maintenance) of NUZYRA is described in Table 1 below.
Loading Doses | Maintenance Dose | Treatment Duration |
---|---|---|
NUZYRA Injection: 200 mg by intravenous infusion over 60 minutes on day 1. OR 100 mg by intravenous infusion over 30 minutes, twice on day 1. OR |
NUZYRA Injection: 100 mg by intravenous infusion over 30 minutes once daily. OR NUZYRA Tablets: 300 mg orally once daily. |
7 to 14 Days |
NUZYRA Tablets: 300 mg orally twice on day 1. |
Dosage in Adults with Acute Bacterial Skin Structure and Skin Infections (ABSSSI)
For treatment of adults with ABSSSI, the recommended dosage regimen (loading and maintenance) of NUZYRA is described in Table 2 below.
Loading Doses | Maintenance Dose | Treatment Duration |
---|---|---|
NUZYRA Injection: 200 mg by intravenous infusion over 60 minutes on day 1. OR 100 mg by intravenous infusion over 30 minutes, twice on day 1. OR |
NUZYRA Injection: 100 mg by intravenous infusion over 30 minutes once daily. OR NUZYRA Tablets: 300 mg orally once daily. |
7 to 14 Days |
NUZYRA Tablets: 450 mg orally once a day on day 1 and day 2. |
Dosage Adjustments in Patients with Renal or Hepatic Impairment
No dosage adjustment is warranted in patients with renal or hepatic impairment [see Clinical Pharmacology (12.3)].
Preparation and Administration of NUZYRA for Injection Intravenous Solution
Reconstitution and Dilution:
- 1)
- NUZYRA must be reconstituted and then further diluted under aseptic conditions. To prepare the required dose for intravenous infusion, reconstitute and dilute the appropriate number of vials, as determined from Table 3 below.
- 2)
- Reconstitute each 100 mg vial of NUZYRA with 5 mL of Sterile Water, 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, for Injection.
- 3)
- Gently swirl the contents and let the vial stand until the cake has completely dissolved and any foam disperses. Do not shake the vial.
- 4)
- The reconstituted NUZYRA solution should be yellow to dark orange in color; if not, the solution should be discarded. Visually inspect the reconstituted NUZYRA solution for particulate matter and discoloration prior to further dilution and administration. If necessary, invert the vial to dissolve any remaining powder and swirl gently to prevent foaming.
- 5)
- Immediately (within 1 hour), withdraw 5 mL or 10 ml of the reconstituted solution and further dilute to a 100 mL (nominal volume) of 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, bag for injection. The concentration of the final diluted infusion solution will either be 1 mg/mL or 2 mg/mL in accordance with Table 3 below. Discard any unused portion of the reconstituted solution.
- 6)
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
NUZYRA for Injection Dose | Number of Vials to Reconstitute for Further Dilution | Volume of Reconstituted Solution (5 mL/vial) to Withdraw for Further Dilution | Final Infusion Concentration of NUZYRA |
---|---|---|---|
200 mg | 2 Vials | 10 mL | 2 mg/mL |
100 mg | 1 Vial | 5 mL | 1 mg/mL |
Storage of the Diluted Infusion Solution
The NUZYRA diluted infusion solution may be used within 24 hours at room temperature (less than or equal to 25°C) or within 7 days when refrigerated (2°C to 8°C). Do not freeze. Allow the infusion bag to reach room temperature prior to use.
Administration
After reconstitution and dilution, administer NUZYRA by intravenous infusion, using a total infusion time of 60 minutes for a 200-mg dose, or a total infusion time of 30 minutes for a 100-mg dose [see Dosage and Administration (2.2, 2.3)].
Administer NUZYRA intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed with 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, before and after infusion of NUZYRA. The compatibility of NUZYRA with other drugs and infusion solutions other than 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP has not been established.